Related references
Note: Only part of the references are listed.Bone Marrow Morphologic Features in Polycythemia Vera With JAK2 Exon 12 Mutations
Meredith A. Lakey et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
LNK Mutations in JAK2 Mutation-Negative Erythrocytosis.
Terra L. Lasho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients
Valerie Ugo et al.
PLOS ONE (2010)
Advances in Understanding and Management of Myeloproliferative Neoplasms
Alessandro M. Vannucchi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera
Susanne Schnittger et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera
D. Olcaydu et al.
LEUKEMIA (2009)
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Damla Olcaydu et al.
NATURE GENETICS (2009)
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Outi Kilpivaara et al.
NATURE GENETICS (2009)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Amy V. Jones et al.
NATURE GENETICS (2009)
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
Sai Li et al.
BLOOD (2008)
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
Francesco Passamonti et al.
BLOOD (2008)
Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis
Amy V. Jones et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Daniela Pietra et al.
BLOOD (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients
C. M. Butcher et al.
LEUKEMIA (2008)
JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis
Luz Martinez-Aviles et al.
HAEMATOLOGICA (2007)
The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels
Melanie J. Percy et al.
HAEMATOLOGICA (2007)
Phenotypic variations and new mutations in JAK2 V617F-neagative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis
Donna M. Williams et al.
EXPERIMENTAL HEMATOLOGY (2007)
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
A. Pardanani et al.
LEUKEMIA (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
F Passamonti et al.
BLOOD (2006)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
